Hypofractionated radiotherapy with or without IGRT in prostate cancer: Preliminary report of acute toxicity

Maurizio Valeriani, Flavia Monaco, Mattia Falchetto Osti, Vitaliana De Sanctis, Giuseppe Minniti, Riccardo Maurizi Enrici

Research output: Contribution to journalArticle

Abstract

Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate cancer. Patients and Methods: We treated 62 patients with intermediate risk prostate cancer. All patients were treated with a total dose of 43.8 Gy on seminal vesicles and 54.75 Gy on prostate, 3.65 Gy per fraction, three times a week for a total of 5 weeks. All patients underwent neoadjuvant, concomitant and adjuvant hormonal therapy. Thirty-six patients were submitted to image-guided radiation therapy (IGRT). Results: Median follow-up was 15 months (range 3-33 months). Toxicities during the treatment were: grade 1-2 gastrointestinal (GI) toxicity, 22.6%; grade 1-2 genitourinary (GU) toxicity, 51.6%. Toxicities 3 months after the end of the treatment were grade 1-2 GI 6.5%, grade 1-2 GU 9.7%. No statistical difference was observed comparing acute toxicity in patients treated with or without IGRT. Conclusion: This study showed that the hypofractionation schedule used is well tolerated, with a low rate of acute grade 1-2 GI toxicity and without major grade (≥3) acute toxicity. Longer follow-up is needed to determine if this low rate of acute toxicity will be translated in a low rate of late toxicity.

Original languageEnglish
Pages (from-to)3555-3558
Number of pages4
JournalAnticancer Research
Volume31
Issue number10
Publication statusPublished - Oct 2011

Fingerprint

Image-Guided Radiotherapy
Prostatic Neoplasms
Radiotherapy
Appointments and Schedules
Seminal Vesicles
Prostate
Therapeutics

Keywords

  • Acute effect
  • Hormonotherapy
  • Hypofractionated radiotherapy
  • Image guided radiation therapy
  • Intermediate risk
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Valeriani, M., Monaco, F., Osti, M. F., De Sanctis, V., Minniti, G., & Enrici, R. M. (2011). Hypofractionated radiotherapy with or without IGRT in prostate cancer: Preliminary report of acute toxicity. Anticancer Research, 31(10), 3555-3558.

Hypofractionated radiotherapy with or without IGRT in prostate cancer : Preliminary report of acute toxicity. / Valeriani, Maurizio; Monaco, Flavia; Osti, Mattia Falchetto; De Sanctis, Vitaliana; Minniti, Giuseppe; Enrici, Riccardo Maurizi.

In: Anticancer Research, Vol. 31, No. 10, 10.2011, p. 3555-3558.

Research output: Contribution to journalArticle

Valeriani, M, Monaco, F, Osti, MF, De Sanctis, V, Minniti, G & Enrici, RM 2011, 'Hypofractionated radiotherapy with or without IGRT in prostate cancer: Preliminary report of acute toxicity', Anticancer Research, vol. 31, no. 10, pp. 3555-3558.
Valeriani M, Monaco F, Osti MF, De Sanctis V, Minniti G, Enrici RM. Hypofractionated radiotherapy with or without IGRT in prostate cancer: Preliminary report of acute toxicity. Anticancer Research. 2011 Oct;31(10):3555-3558.
Valeriani, Maurizio ; Monaco, Flavia ; Osti, Mattia Falchetto ; De Sanctis, Vitaliana ; Minniti, Giuseppe ; Enrici, Riccardo Maurizi. / Hypofractionated radiotherapy with or without IGRT in prostate cancer : Preliminary report of acute toxicity. In: Anticancer Research. 2011 ; Vol. 31, No. 10. pp. 3555-3558.
@article{6650c864561d4c4b96e0e329b86f0de9,
title = "Hypofractionated radiotherapy with or without IGRT in prostate cancer: Preliminary report of acute toxicity",
abstract = "Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate cancer. Patients and Methods: We treated 62 patients with intermediate risk prostate cancer. All patients were treated with a total dose of 43.8 Gy on seminal vesicles and 54.75 Gy on prostate, 3.65 Gy per fraction, three times a week for a total of 5 weeks. All patients underwent neoadjuvant, concomitant and adjuvant hormonal therapy. Thirty-six patients were submitted to image-guided radiation therapy (IGRT). Results: Median follow-up was 15 months (range 3-33 months). Toxicities during the treatment were: grade 1-2 gastrointestinal (GI) toxicity, 22.6{\%}; grade 1-2 genitourinary (GU) toxicity, 51.6{\%}. Toxicities 3 months after the end of the treatment were grade 1-2 GI 6.5{\%}, grade 1-2 GU 9.7{\%}. No statistical difference was observed comparing acute toxicity in patients treated with or without IGRT. Conclusion: This study showed that the hypofractionation schedule used is well tolerated, with a low rate of acute grade 1-2 GI toxicity and without major grade (≥3) acute toxicity. Longer follow-up is needed to determine if this low rate of acute toxicity will be translated in a low rate of late toxicity.",
keywords = "Acute effect, Hormonotherapy, Hypofractionated radiotherapy, Image guided radiation therapy, Intermediate risk, Prostate cancer",
author = "Maurizio Valeriani and Flavia Monaco and Osti, {Mattia Falchetto} and {De Sanctis}, Vitaliana and Giuseppe Minniti and Enrici, {Riccardo Maurizi}",
year = "2011",
month = "10",
language = "English",
volume = "31",
pages = "3555--3558",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Hypofractionated radiotherapy with or without IGRT in prostate cancer

T2 - Preliminary report of acute toxicity

AU - Valeriani, Maurizio

AU - Monaco, Flavia

AU - Osti, Mattia Falchetto

AU - De Sanctis, Vitaliana

AU - Minniti, Giuseppe

AU - Enrici, Riccardo Maurizi

PY - 2011/10

Y1 - 2011/10

N2 - Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate cancer. Patients and Methods: We treated 62 patients with intermediate risk prostate cancer. All patients were treated with a total dose of 43.8 Gy on seminal vesicles and 54.75 Gy on prostate, 3.65 Gy per fraction, three times a week for a total of 5 weeks. All patients underwent neoadjuvant, concomitant and adjuvant hormonal therapy. Thirty-six patients were submitted to image-guided radiation therapy (IGRT). Results: Median follow-up was 15 months (range 3-33 months). Toxicities during the treatment were: grade 1-2 gastrointestinal (GI) toxicity, 22.6%; grade 1-2 genitourinary (GU) toxicity, 51.6%. Toxicities 3 months after the end of the treatment were grade 1-2 GI 6.5%, grade 1-2 GU 9.7%. No statistical difference was observed comparing acute toxicity in patients treated with or without IGRT. Conclusion: This study showed that the hypofractionation schedule used is well tolerated, with a low rate of acute grade 1-2 GI toxicity and without major grade (≥3) acute toxicity. Longer follow-up is needed to determine if this low rate of acute toxicity will be translated in a low rate of late toxicity.

AB - Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate cancer. Patients and Methods: We treated 62 patients with intermediate risk prostate cancer. All patients were treated with a total dose of 43.8 Gy on seminal vesicles and 54.75 Gy on prostate, 3.65 Gy per fraction, three times a week for a total of 5 weeks. All patients underwent neoadjuvant, concomitant and adjuvant hormonal therapy. Thirty-six patients were submitted to image-guided radiation therapy (IGRT). Results: Median follow-up was 15 months (range 3-33 months). Toxicities during the treatment were: grade 1-2 gastrointestinal (GI) toxicity, 22.6%; grade 1-2 genitourinary (GU) toxicity, 51.6%. Toxicities 3 months after the end of the treatment were grade 1-2 GI 6.5%, grade 1-2 GU 9.7%. No statistical difference was observed comparing acute toxicity in patients treated with or without IGRT. Conclusion: This study showed that the hypofractionation schedule used is well tolerated, with a low rate of acute grade 1-2 GI toxicity and without major grade (≥3) acute toxicity. Longer follow-up is needed to determine if this low rate of acute toxicity will be translated in a low rate of late toxicity.

KW - Acute effect

KW - Hormonotherapy

KW - Hypofractionated radiotherapy

KW - Image guided radiation therapy

KW - Intermediate risk

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=80054772208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054772208&partnerID=8YFLogxK

M3 - Article

C2 - 21965777

AN - SCOPUS:80054772208

VL - 31

SP - 3555

EP - 3558

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -